Fascinating preprint (H/T @zeynep ) - in host diversity is quite limited (i.e. variants aren't emerging from typical infections spreading)
This really brings up the concept of making sure our immunocompromised patients are followed up appropriately, and vaccines are pushedhttps://twitter.com/KATarinambraun/status/1388312255222124544 …
-
-
I think BMJ/WHO is going to hopefully weigh in on this given the multiple negative trials (RECOVERY, REMAP-CAP, CONCOR-1) for convalescent plasma to formally not recommend it's use period - as it doesn't seem to have any benefit.
-
Great. I hope they don't just say "not useful" but strongly point out this issue as well. In many LMIC countries "not useful" isn't enough to stop widespread use if seen as "can't hurt" especially if there aren't many alternative effective therapeutics. Need strong language.
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.
We deep seq’d
carefully at long-term infxs.
1/12